Participated · Series B · Jun 2026

Ona Therapeutics is a spin-off from IRB Barcelona and ICREA that develops precision-engineered antibody-drug conjugates (ADCs) to target treatment-resistant cancers. The company uses a proprietary, patient-driven discovery platform to identify tumor-specific antigens and epitopes that enable efficient internalization and targeted payload delivery. Its lead clinical program is ONA-255, initially focused on breast cancer, and it is also advancing ONA-389 targeting colorectal cancer. The company integrates target validation, antibody engineering, optimized payload selection and validated linker-payload technologies in its ADC development approach. Led by CEO Valerie Vanhooren, Ona plans to use the Series B proceeds to advance clinical development of its lead and second programs. The article does not disclose revenue, user metrics or a company valuation.

Participated · Series A · Dec 2025

TargED Biopharmaceuticals B.V., founded in 2020 as a spin-out from University Medical Center Utrecht, is focused on TGD001, an antibody-enzyme fusion protein that binds von Willebrand factor (VWF) and degrades both VWF and fibrin to dissolve clots. The therapy has completed a Phase 1 first-in-human study that showed a favorable safety profile with no spontaneous bleeding events and potent thrombolytic activity. With its latest funding, the company will initiate two Phase 1/2 clinical studies targeting acute ischemic stroke and thrombotic microangiopathies, expanding trial sites across Europe and the U.S. and aiming for first data in 2026. Unlike approved thrombolytics that target a single pathway, TGD001 leverages the ubiquitous presence of VWF to enable broad clot dissolution. TargED has raised over €60 million in Series A financing to date and also received a blended-finance grant from the European Innovation Council Accelerator in 2025. The fresh capital strengthens its balance sheet and accelerates clinical development toward demonstrating proof-of-concept in multiple life-threatening indications.

Participated · Series C · Oct 2025

Tubulis is a Munich-based biotechnology company engineering uniquely matched antibody-drug conjugates with enhanced biophysical properties for improved on-tumor delivery and wider therapeutic windows. Its proprietary Tubutecan and other ADC platform technologies underpin a growing pipeline designed for high-need solid tumor indications. The lead program, TUB-040 targeting NaPi2b, has shown early clinical proof-of-concept in platinum-resistant high-grade serous ovarian cancer, demonstrating anti-tumor activity at low doses with favorable safety. A second clinical-stage candidate, TUB-030, targets 5T4, and several additional ADCs remain in preclinical development. Proceeds from the company’s latest financing will fund pivotal trials of TUB-040, evaluations in earlier-line ovarian cancer, combination regimens and broader solid tumor exploration. The capital will also advance TUB-030 and preclinical assets while driving further innovation of Tubulis’ ADC technologies for internal programs and partnerships. To date, the firm has secured €344 million (US $401 million) in Series C funding from a global syndicate of life-science investors.

Participated · Series A · Jan 2025

Coave Therapeutics is a genetic medicines company based in Paris that develops technologies to improve genetic medicine delivery. Its proprietary ALIGATER™ platform is designed to enhance targeting, specificity, efficacy and manufacturability of genetic medicines. The company is focused on overcoming gene therapy delivery challenges to extra-hepatic tissues and is building a pipeline targeting CNS, neuromuscular and eye diseases. Led by CEO Rodolphe Clerval, Coave positions ALIGATER as a platform with broad clinical applications. The company raised €32M in a Series A to advance the ALIGATER platform. Emmanuelle Coutanceau from Novo Holdings and Jean Francois Morin from Bpifrance will join Coave’s board of directors in connection with the financing. Coave Therapeutics develops targeted genetic medicines using its proprietary ALIGATER™ platform, which chemically modifies AAV capsids or lipid nanoparticles to improve efficacy, safety, and manufacturability. The company’s conjugated vectors (coAAV) enable targeted delivery to the central nervous system and the eye, achieving improved transduction and biodistribution across species at low doses. Its lead disclosed program in the article, CTx-TFEB, is a coAAV-delivered TFEB gene therapy designed to promote autophagy and clear toxic protein aggregates in neurons as a potential pan-ALS treatment. Coave recently received grant funding from the ALS Association to advance CTx-TFEB through preclinical proof-of-concept and aims to establish robust preclinical data to support a clinical transition. The company is headquartered in Paris, France and states its pipeline targets both rare and prevalent neurodegenerative and ocular indications. Coave is backed by unnamed international life sciences investors mentioned in the company description. Coave Therapeutics is a clinical-stage biotech advancing gene therapies for rare ocular and CNS diseases using its AAV-Ligand Conjugate (ALIGATER) platform. Its lead candidate, CTx-PDE6b, is a first-in-class AAV-based gene therapy designed to deliver a full-length functional PDE6b gene for PDE6b-associated retinitis pigmentosa and is currently in a Phase I/II trial. The company has entered a licensing and co-development partnership with Théa Open Innovation to advance CTx-PDE6b through clinical development and commercialization in Europe and adjacent territories. Under the agreement Coave will co-develop the program with Théa and share development costs while retaining commercialization rights outside the partner territories, including the US. Financially, Coave will receive an upfront payment and an equity investment of €10 million and is eligible to receive up to €65 million in development, regulatory and commercial milestone payments, plus double-digit royalties on net sales in licensed territories. Coave is headquartered in Paris and is backed by investors including Seroba Life Sciences, Théa Open Innovation, eureKARE, Fund+, Omnes Capital, V-Bio Ventures, Kurma Partners, Idinvest, GO Capital and Sham Innovation Santé/Turenne. Coave Therapeutics, led by CEO Rodolphe Clerval and based in Paris, is advancing targeted gene therapies using its AAV-Ligand Conjugate (ALIGATER) platform to enhance AAV delivery and transduction. The company is progressing a pipeline that includes the lead clinical program CTx-PDE6b, currently in a Phase I/II trial, and preclinical candidates such as CTx-GBA1 (Parkinson’s disease and Gaucher disease) and CTx-ABCA4 (Stargardt’s disease). Coave will use proceeds to push CTx-PDE6b toward pivotal trials, further develop the ALIGATER platform, advance new preclinical coAAV programs in rare CNS and ocular diseases, and seek partnerships to accelerate clinic entry. The company is clinical-stage and focused on producing targeted gene therapy products via proprietary chemical conjugation of AAV vectors. Financially, the company has raised a total of €33.1M following the Series B expansion.

Participated · Series B · Jul 2024

Confo Therapeutics employs a proprietary discovery platform using conformation-specific ConfoBodies® to stabilize GPCRs in functionally relevant states and discover small molecules and agonistic antibodies. The company is building a pipeline focused on metabolic and endocrine diseases, including programs directed at obesity and severe rare endocrine disorders. Confo plans to advance two wholly owned programs through Phase 1 and bring two additional programs to IND approval, with explicit efforts on molecules targeting GPR75 for obesity. The company emphasizes both small-molecule GPCR modulators and therapeutic antibodies, notably agonistic antibodies. Confo is headquartered in Ghent, Belgium. Its current financial position includes the recently closed EUR 60M Series B financing to accelerate its development pipeline. Confo Therapeutics develops ConfoBodyTM single-domain camelid antibodies that selectively stabilize G-protein coupled receptors (GPCRs) to enable drug discovery. The company is building a portfolio of first-in-class programs based on its Confo® technology. It operates both internal discovery programs and revenue-generating partnerships with pharma on non-competing GPCR targets. Confo Therapeutics has active collaborations with Lundbeck and Roche to apply its platform. The firm plans to use new capital to advance its pipeline of GPCR-modulating compounds toward clinical candidates. The company was co-founded in 2015 as a VUB–VIB spin-off and is based in Ghent, Belgium. Confo Therapeutics is an emerging drug-discovery company based in Ghent, Belgium, that uses its proprietary Confo® technology to discover new GPCR agonist compounds for the treatment of fibrosis. The company operates a Drug Discovery Center in Gent and a Target Discovery Center in Brussels. It is expanding the applicability of its Confo® platform, supported by recent grant awards. Financially, Confo Therapeutics has been awarded non-dilutive funding totaling roughly €2.6 million to support its discovery programs. Part of the funding will be allocated over a two-year VLAIO grant primarily to the Gent Drug Discovery Center, while the Innoviris award will support work at the Brussels Target Discovery Center. The company’s near-term plans, as described in the awards, focus on fibrosis compound discovery and broadening the Confo® technology’s use.